Zentalis Pharmaceuticals (ZNTL) Operating Leases (2020 - 2026)

Zentalis Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $38.7 million for Q1 2026.

• In Q1 2026, Operating Leases fell 8.32% year-over-year to $38.7 million; the TTM figure through Mar 2026 stood at $38.7 million (down 8.32% YoY), while the FY2025 annual figure was $35.7 million, down 9.79% from the prior year.
• Operating Leases for Q1 2026 stood at $38.7 million, up from $35.7 million in the prior quarter.
• The five-year high for Operating Leases was $47.0 million in Q1 2023, with the low at $35.7 million in Q4 2025.
• The 5-year median for Operating Leases is $42.7 million (2023), against an average of $41.9 million.
• The sharpest annual moves came in 2022 and 2025: Operating Leases rose 1.59% in 2022, then slipped 9.79% in 2025.
• Zentalis Pharmaceuticals' Operating Leases stood at $45.2 million in 2022, then declined by 4.46% to $43.2 million in 2023, then retreated by 8.28% to $39.6 million in 2024, then declined by 9.79% to $35.7 million in 2025, then rose by 8.25% to $38.7 million in 2026.
• Business Quant data shows ZNTL's Operating Leases at $38.7 million in Q1 2026, $35.7 million in Q4 2025, and $36.7 million in Q3 2025.